Physician profile
Talal I Mousallem
NPI 1487812749
$52,135.27
in general payments reported to CMS, 2019-2025
10 companies · $29K in 2025
The $29K reported for 2025 was more than what 94% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,500 · 2022: $216 · 2023: $2,446 · 2024: $18K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Travel and Lodging: $12K · Honoraria: $6,908 · Food and Beverage: $2,222 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,850.30 |
| Travel and Lodging | $12,360.81 |
| Honoraria | $6,907.50 |
| Food and Beverage | $2,222.40 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $29,059.08 | 2021-2025 | Revcovi |
| Pharming Healthcare, INC. | $6,990.93 | 2024-2025 | Joenja, Ruconest |
| Grifols USA, LLC | $6,928.94 | 2022-2024 | Xembify, Gamunex-C |
| Amgen INC. | $5,881.07 | 2023-2025 | Actimmune, Tezspire |
| Horizon Therapeutics Plc | $1,822.50 | 2023 | Actimmune |
| Adma Biomanufacturing LLC | $750.32 | 2022-2025 | |
| Csl Behring | $464.44 | 2024-2025 | Hizentra |
| Astrazeneca Pharmaceuticals Lp | $110.00 | 2023 | Tezspire |
| Sobi, INC | $77.99 | 2024 | |
| Sumitomo Pharma America, INC. | $50.00 | 2023 | Rethymic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talal Mousallem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.